Literature DB >> 20565475

The influence of chromatin structure on DNA damage induced by nitrogen mustard and cisplatin analogues.

Anne M Galea1, Vincent Murray.   

Abstract

The interaction of anti-tumour drugs with reconstituted chromatin has been investigated using defined nucleosomal complexes. This allowed the effect of nucleosome cores on drug-induced DNA damage to be assessed for four nitrogen mustard analogues, dimethylsulphate and three cisplatin analogues. A defined nucleosomal complex was employed that contained two precisely positioned nucleosome cores. The construct was then subjected to drug treatment, and the resulting DNA damage was quantitatively analysed using a Taq DNA polymerase stop assay. At the sites of damage, densitometric comparisons between purified and reconstituted DNA were used to evaluate the influence of nucleosomal core proteins on specific drug-DNA interactions. Results were combined with previous data obtained for other DNA-damaging drugs investigated using the same nucleosomal construct. For most of the DNA-damaging agents studied, this method revealed protection at the positioned nucleosome cores and indicated that the preferred site of DNA binding for these compounds was in the linker region of the construct. Statistical analyses confirmed the significant level of damage protection conferred by the nucleosome cores and revealed differences between the examined compounds. Larger compounds generally displayed a greater tendency to target the linker region of the nucleosomal DNA and were impeded from damaging nucleosomal core DNA. In contrast, smaller molecules had greater access to nucleosomal core DNA.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20565475     DOI: 10.1111/j.1747-0285.2010.00969.x

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  9 in total

1.  The DNA sequence specificity of bleomycin cleavage in a systematically altered DNA sequence.

Authors:  Shweta D Gautam; Jon K Chen; Vincent Murray
Journal:  J Biol Inorg Chem       Date:  2017-05-16       Impact factor: 3.358

2.  Identification of small molecule proliferating cell nuclear antigen (PCNA) inhibitor that disrupts interactions with PIP-box proteins and inhibits DNA replication.

Authors:  Chandanamali Punchihewa; Akira Inoue; Asami Hishiki; Yoshihiro Fujikawa; Michele Connelly; Benjamin Evison; Youming Shao; Richard Heath; Isao Kuraoka; Patrick Rodrigues; Hiroshi Hashimoto; Masanobu Kawanishi; Mamoru Sato; Takashi Yagi; Naoaki Fujii
Journal:  J Biol Chem       Date:  2012-03-01       Impact factor: 5.157

3.  Zorbamycin has a different DNA sequence selectivity compared with bleomycin and analogues.

Authors:  Jon K Chen; Dong Yang; Ben Shen; Brett A Neilan; Vincent Murray
Journal:  Bioorg Med Chem       Date:  2016-09-30       Impact factor: 3.641

4.  Consequences of cisplatin binding on nucleosome structure and dynamics.

Authors:  Ryan C Todd; Stephen J Lippard
Journal:  Chem Biol       Date:  2010-12-22

5.  Novel therapeutic combination demonstrates more than additive effects in cutaneous T-cell lymphoma.

Authors:  Brittany O'Neill Dulmage; Sara K Story; Louis D Falo; Larisa J Geskin
Journal:  Leuk Lymphoma       Date:  2015-01-21

6.  The genome-wide DNA sequence specificity of the anti-tumour drug bleomycin in human cells.

Authors:  Vincent Murray; Jon K Chen; Mark M Tanaka
Journal:  Mol Biol Rep       Date:  2016-05-17       Impact factor: 2.316

7.  The anti-tumor drug bleomycin preferentially cleaves at the transcription start sites of actively transcribed genes in human cells.

Authors:  Vincent Murray; Jon K Chen; Anne M Galea
Journal:  Cell Mol Life Sci       Date:  2013-08-28       Impact factor: 9.261

8.  The determination of the DNA sequence specificity of bleomycin-induced abasic sites.

Authors:  Jon K Chen; Vincent Murray
Journal:  J Biol Inorg Chem       Date:  2016-03-03       Impact factor: 3.358

Review 9.  The Interaction of the Metallo-Glycopeptide Anti-Tumour Drug Bleomycin with DNA.

Authors:  Vincent Murray; Jon K Chen; Long H Chung
Journal:  Int J Mol Sci       Date:  2018-05-04       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.